[go: up one dir, main page]

BRPI0509878A - essential fatty acids in the prevention and / or treatment of depression in patients with coronary artery or heart disease - Google Patents

essential fatty acids in the prevention and / or treatment of depression in patients with coronary artery or heart disease

Info

Publication number
BRPI0509878A
BRPI0509878A BRPI0509878-5A BRPI0509878A BRPI0509878A BR PI0509878 A BRPI0509878 A BR PI0509878A BR PI0509878 A BRPI0509878 A BR PI0509878A BR PI0509878 A BRPI0509878 A BR PI0509878A
Authority
BR
Brazil
Prior art keywords
depression
patients
prevention
treatment
heart disease
Prior art date
Application number
BRPI0509878-5A
Other languages
Portuguese (pt)
Inventor
Cees-Nico Verboom
Rainer Oelze
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Publication of BRPI0509878A publication Critical patent/BRPI0509878A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

áCIDOS GRAXOS ESSENCIAIS NA PREVENçãO E/OU TRATAMENTO DA DEPRESSãO EM DOENTES COM DOENçA ARTERIAL OU CARDìACA CORONáRIA. A presente invenção refere-se à utilização de uma composição farmacêutica que contém ésteres etílicos de ácidos graxas essenciais originários de óleos de peixe, em particular como uma mistura de concentração elevada de ésteres etílicos de ácido eicosapentanóico (EPA) (20:5<sym>3) e ácido docosahexanóico (DHA) (22:6<sym>3) na prevenção e/ou tratamento da depressão em doentes com doença cardiovascular, tal como doença cardíaca coronária e/ou arterial coronária ou vascular.ESSENTIAL FATTY ACIDS IN PREVENTION AND / OR TREATMENT OF DEPRESSION IN PATIENTS WITH ARTERIAL OR CORONARY HEART DISEASE. The present invention relates to the use of a pharmaceutical composition containing essential fatty acid ethyl esters originating from fish oils, in particular as a high concentration mixture of eicosapentaenoic acid (EPA) ethyl esters (20: 5 <sym> 3) and docosahexanoic acid (DHA) (22: 6 <sym> 3) in the prevention and / or treatment of depression in patients with cardiovascular disease, such as coronary heart disease and / or coronary or vascular disease.

BRPI0509878-5A 2004-04-16 2005-04-15 essential fatty acids in the prevention and / or treatment of depression in patients with coronary artery or heart disease BRPI0509878A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04101578 2004-04-16
PCT/EP2005/004031 WO2005110393A1 (en) 2004-04-16 2005-04-15 Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease

Publications (1)

Publication Number Publication Date
BRPI0509878A true BRPI0509878A (en) 2007-10-16

Family

ID=34928968

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509878-5A BRPI0509878A (en) 2004-04-16 2005-04-15 essential fatty acids in the prevention and / or treatment of depression in patients with coronary artery or heart disease

Country Status (12)

Country Link
EP (1) EP1765319A1 (en)
JP (1) JP2007532605A (en)
CN (1) CN1942180A (en)
AU (1) AU2005244483B2 (en)
BR (1) BRPI0509878A (en)
CA (1) CA2504280A1 (en)
IL (1) IL178300A0 (en)
MX (1) MX291518B (en)
RU (1) RU2387448C2 (en)
UA (1) UA94693C2 (en)
WO (1) WO2005110393A1 (en)
ZA (1) ZA200607794B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2421909A (en) * 2004-12-23 2006-07-12 Laxdale Ltd Pharmaceutical compositions comprising EPA and methods of use
ITMI20100961A1 (en) * 2010-05-27 2011-11-28 Erredue Spa MIXTURES RICH IN OMEGA-3 FATTY ACIDS, THEIR COMPOSITIONS AND THEIR PREPARATION PROCESS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048788A1 (en) * 1997-04-29 1998-11-05 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
IT1308613B1 (en) * 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa ESSENTIAL FATTY ACIDS IN THE PREVENTION OF CARDIOVASCULAR EVENTS.
GB9916536D0 (en) * 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
CN1268328C (en) * 2001-05-30 2006-08-09 拉克斯戴尔有限公司 Coenzyme q and eicosapentaenoic acid (EPA)

Also Published As

Publication number Publication date
RU2387448C2 (en) 2010-04-27
CA2504280A1 (en) 2005-10-16
CN1942180A (en) 2007-04-04
RU2006140277A (en) 2008-05-27
WO2005110393A1 (en) 2005-11-24
EP1765319A1 (en) 2007-03-28
UA94693C2 (en) 2011-06-10
MX291518B (en) 2011-10-31
AU2005244483A1 (en) 2005-11-24
MXPA06011940A (en) 2006-12-15
JP2007532605A (en) 2007-11-15
IL178300A0 (en) 2007-02-11
ZA200607794B (en) 2008-05-28
AU2005244483B2 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
Singer et al. Slow desaturation and elongation of linoleic and α-linolenic acids as a rationale of eicosapentaenoic acid-rich diet to lower blood pressure and serum lipids in normal, hypertensive and hyperlipemic subjects
Stillwell et al. Docosahexaenoic acid: membrane properties of a unique fatty acid
Mozaffarian et al. (n-3) fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary?
Horrobin et al. Eicosapentaenoic acid and arachidonic acid: collaboration and not antagonism is the key to biological understanding
EA200300830A1 (en) INDISPENSABLE N-3 FATTY ACIDS IN TREATMENT OF HEART FAILURE AND HEART DECOMPENSATION
BRPI0408006A (en) use of omega-3 fatty acids in the treatment of diabetic patients
DE60000133C5 (en) ESSENTIAL FATTY ACIDS FOR PREVENTING CARDIOVASCULAR ATTACHMENTS
TR201908522T4 (en) Ketone bodies and ketone body esters as blood lipid lowering agents.
WO2007103160A3 (en) Stearidonic acid for improving cardiovascular health
JPS60115522A (en) Composite fatty acid composition for lowering cholesterol and triglyceride level in blood
AR062305A1 (en) METHODS TO IMPROVE OSEA HEALTH AND MUSCLE HEALTH
Shahidi Omega-3 fatty acids and marine oils in cardiovascular and general health: A critical overview of controversies and realities
WO2007070611A3 (en) Nutritional supplement containing long-chain polyunsaturated fatty acids
IL192366A (en) Omega 3 fatty acid formulations
NZ627238A (en) Stable pharmaceutical composition comprising ethyl eicosapentaenoate
CN1471391A (en) Compositions and methods for treating hypertriglyceridemia
CO6150156A2 (en) DHA ESTERES AND ITS USE IN THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES
JP2008525392A (en) Treatment of severe melancholic depression with EPA
NO20076382L (en) Use of docosahexa glycerides in the treatment of tumorigenic diseases
JP2008050367A5 (en)
WO2003072111A3 (en) Omega-3 fatty acids or omega-3 phosphatidylcholine in the treatment of depression
Radcliffe et al. Controversies in omega-3 efficacy and novel concepts for application
ATE424732T1 (en) PREPARATIONS CONTAINING POLYUNSATURATED PHOSPHOLIPIDES, MONOTERPENES AND TRYPTOPHAN AND/OR PHYTOL DERIVATIVES
BRPI0509878A (en) essential fatty acids in the prevention and / or treatment of depression in patients with coronary artery or heart disease
WO2006111633A3 (en) Use of lecithin as a medicament for treating psoriasis

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: ABBOTT PRODUCTS GMBH (DE)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2308 DE 31/03/2015.